Iowa House Bill HF383

Iowa 2025-2026 Regular Session

• Introduced: 2/13/25
• Engrossed: 2/20/25
• Refer: 2/24/25
• Enrolled: 5/19/25
• Vetoed: 6/11/25

Caption

A bill for an act relating to the controlled substance crystalline polymorph psilocybin. (Formerly HF 14.) Vetoed 6-11-25.

Impact

If enacted, HF383 will significantly alter the legal landscape regarding the use of psilocybin within the state of Iowa. By aligning state law with federal guidelines, the bill would allow medical practitioners to prescribe psilocybin under controlled conditions, potentially broadening access for patients seeking alternative therapeutic options. This shift could pave the way for research and clinical trials focused on psilocybin's benefits in mental health treatment, which are gaining traction in various jurisdictions around the country.

Summary

House File 383 (HF383) is a legislative measure concerning the classification and regulation of crystalline polymorph psilocybin, a drug that has gained attention for its therapeutic potential. The bill aims to amend the Iowa Code to allow for the removal of this compound from Schedule I of controlled substances once it receives approval from the United States Food and Drug Administration (FDA). Subsequent to this federal approval, the bill would facilitate the lawful prescription, distribution, and marketing of psilocybin, thereby enabling further exploration of its use in medical treatments.

Sentiment

The sentiment surrounding HF383 appears to be positive, with broad support indicated during the voting process—the bill passed with a unanimous vote of 46 in favor and none against. Support for the bill is likely driven by growing recognition of the therapeutic potential of psilocybin, particularly in treating conditions such as depression and anxiety. Legislators and stakeholders advocating for mental health advancements may perceive this bill as a progressive step towards improving healthcare options for residents.

Contention

Notable points of contention surrounding the bill may include discussions about the implications of legalizing another controlled substance and the potential risks versus benefits associated with psilocybin use. While proponents highlight the drug's therapeutic properties, opponents may raise concerns about safety, regulation, and the possibility of misuse. The successful passage of HF383 reflects a significant shift in public and legislative attitudes towards psychedelic substances, yet ongoing debates about their implementation and monitoring are expected.